Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis with Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
(Presenting Author: Emery, P.
Case 1- A 74-year-old female with RA (Steinbrocker classification: functional class III, stage of disease progression 4) who was first diagnosed in 1973 was treated with non-biological disease-modifying antirheumatic drugs
Women with autoimmune diseases who take corticosteroids and disease-modifying antirheumatic drugs
later in pregnancy have an increased risk of preterm birth, but this association is largely explained by confounding with sociodemographic and clinical factors and disease severity, a study showed.
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs
and biologic agents in the treatment of rheumatoid arthritis.
Although many disease-modifying antirheumatic drugs
(DMARDs) and biologic agents are used in the treatment of this disease, new pharmaceutical drugs are required to achieve better efficacy.
Cost-effectiveness of combination nonbiologic disease-modifying antirheumatic drug
strategies in patients with early rheumatoid arthritis.
Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs
, including methotrexate (unless contraindicated), has been inadequate.
The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response to, or were intolerant of, at least one conventional disease-modifying antirheumatic drug
The open-label phase involved 207 patients with baseline moderate to severe active RA on a stable regimen of disease-modifying antirheumatic drug
First New Oral Disease-Modifying Antirheumatic Drug
(DMARD) for RA in More Than 10 Years
rheumatologists would prescribe apremilast (Celgene's Otezla) to 10 percent of their disease-modifying antirheumatic drug
(DMARD)-treated PsA patients, if it was priced at a 35 percent discount to Amgen/Pfizer/Takeda Pharmaceutical's Enbrel.
Cohen of Metroplex Clinical Research Center, Dallas, cited several "prebiologic era" studies, including one 1996 randomized controlled trial of 285 patients who stopped nonbiologic disease-modifying antirheumatic drug
therapy after achieving the "quite stringent" 1981 ACR/ARA remission definitions for 1 year.